Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.

ABSTRACT:

Objective

Persons with schizophrenia die earlier than the general population, in large part due to cardiovascular disease. The study objective was to examine effects of different antipsychotic treatments on estimates of 10-year coronary heart disease (CHD) risk calculated by the Framingham Heart Study formula.

Method

Change in 10-year risk for CHD was compared between treatment groups in 1125 patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial.

Results

The covariate-adjusted mean change in 10-year CHD risk differed significantly between treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3) increase; whereas risk de

SUBMITTER: Daumit GL 

PROVIDER: S-EPMC2614656 | biostudies-literature | 2008 Oct

REPOSITORIES: biostudies-literature